BALTIMORE, Sept. 11, 2024 ~ In a recent press release, Previse, a company specializing in gastrointestinal health, announced the publication of a study in Diagnostics showcasing the analytical validation of their groundbreaking DNA methylation test, Esopredict. This test is designed to identify patients with precancerous Barrett's esophagus (BE) who are at risk of developing high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC) in the future.

According to Sarah Laun, PhD and Vice President of Research and Development at Previse, this new study serves as a complement to Esopredict's previously published clinical validation study. Laun stated that the results of this analytical validation demonstrate the strong performance of the Esopredict assay, which is conducted in Previse's CLIA laboratory located in Baltimore.

More on Marylandian

• GDE Tree Services Expands Operations into Sydney, NSW
• Tuckwell Machinery Expands CNC Range to Support Australian Cabinet Makers
• The Inner Power of Emotional Self-Leadership
• Dr. Nadene Rose Shares the Secret to True Success: Faith, Obedience, and Divine Purpose
• Understanding Unexpected Death: Why Independent Autopsies Matter in Cases Without Clear Cause

The publication, titled "Analytical Validation of Esopredict: An Epigenetic Prognostic Assay for Patients with Barrett's Esophagus," provides rigorous confirmation of the robustness and reproducibility of Esopredict. The data also showcases the high precision and reproducibility of the assay across various levels of risk. This further solidifies Esopredict as a reliable tool for identifying patients at risk for developing BE-related cancers.

---

Show All News | Report Violation